Ceftolozane/Tazobactam Continuous Intravenous Infusion given in an Outpatient Setting to treat Infective Exacerbations of Cystic Fibrosis and Bronchiectasis

Phase 4

• Conditions: Bronchiectasis; Cystic Fibrosis; Human Genetics and Inherited Disorders - Cystic fibrosis; Respiratory - Other respiratory disorders / diseases

• Registration Number: ACTRN12623000976684
• Lead Sponsor: Sunshine Coast Hospital and Health Service

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-09-07
• Last Update Posted: 12 September 2023

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

•Age > 18 years
•Diagnosis of CF or bronchiectasis
•Colonised with pseudomonas aeruginosa or burkholderia cepacia species, with documented isolation of either organism in sputum in the preceding 6 months in the case of non-CF patients, and 2 years in the case of CF patients.
•Current infectious exacerbation requiring treatment with intravenous antibiotics, suitable to be managed on OPAT
•Productive of sputum

Exclusion Criteria

•Unable to consent
•Current pregnancy (as confirmed by urine beta-HCG) or partner who is currently pregnant
•Current breastfeeding
•Not appropriate for OPAT (as determined by treating clinician)
•Estimated CrCl < 50mL/min
•History of hypersensitivity reaction to piperacillin/tazobactam or members of the cephalosporin class of antibiotics
•Unable to expectorate

Study & Design

• Study Type: Interventional
• Study Design: Not specified